NextPoint Therapeutics, founded in 2020 and based in Cambridge, Massachusetts, is advancing the field of immuno-oncology by developing a new class of monotherapies that target the HHLA pathway. Their goal is to provide treatment options for patients who do not benefit from PD-1/L inhibitors. The company's team of proven drug developers is focused on expanding the benefit of immunotherapies to cancer patients by modulating both the adaptive and innate immune systems. NextPoint identifies antibodies against next-generation immune-oncology targets and is building a strategic pipeline of first-in-class immunotherapies. Recently, Axel Hoos, MD, PhD, joined NextPoint Therapeutics' Board of Directors, further strengthening the company's expertise in the field.